ebulized fluticasone propionate, a viable alternative to systemic route in the management of childhood moderate asthma attack: A double-blind, double-dummy study

Completed

• Conditions: Asthma attack; Inflammatory and Immune System - Allergies; Respiratory - Asthma

• Registration Number: ACTRN12615000096550
• Lead Sponsor: Safa Baris

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-02-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Asthma attack patients who have pulmonary index score between 6 and 12 and/or peak expiratory flow of 60-80% predicted after three doses of nebulized salbutamol at Emergency Room (ER).

Exclusion Criteria

children with concomitant cardiopulmonary disease, systemic CS use during the last 2 weeks prior to the exacerbation, admission to hospital (including patients requiring intense effort to breath, altered state of consciousness, bradycardia, room air oxygen saturation of less than 88%)

Study & Design

• Study Type: Interventional
• Study Design: Not specified